I'm not in this based on current financials. I'm in this because anatabine suppresses the activation of NF-kB, and because anatabine is a MAO inhibitor (think about e-cigarettes) and because the company has good patent coverage. Current financials are not significant as long as sales keep rising and margins improve because of better sales / costs ratio.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.